<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MOZOBIL- plerixafor solution </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">      These highlights do not include all the information needed to use MOZOBIL safely and effectively.  See full prescribing information for MOZOBIL.<br><br>MOZOBIL (plerixafor) Injection, for subcutaneous use<br>      Initial U.S. Approval: 2008</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%">
<tbody class="Headless"><tr>
<td align="left">Dosage and Administration (<a href="#S2.1">2.1</a>, <a href="#S2.3">2.3</a>) </td>
<td align="right">08/2015</td>
</tr></tbody>
</table></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta"> Mozobil, a hematopoietic stem cell mobilizer, is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>. (<a href="#S1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul>
<li>Initiate Mozobil treatment after the patient has received G-CSF once daily for 4 days. (<a href="#S2.1">2.1</a>)</li>
<li>Repeat Mozobil dose up to 4 consecutive days. (<a href="#S2.1">2.1</a>)</li>
<li>Dose based on patient weight 									<ul class="Square">
<li>≤ 83 kg: 20 mg dose or select dose based on 0.24 mg/kg actual body weight. (<a href="#S2.1">2.1</a>)</li>
<li>&gt; 83 kg: select dose based on 0.24 mg/kg actual body weight.(<a href="#S2.1">2.1</a>)</li>
</ul>
</li>
<li>Administer by subcutaneous injection approximately 11 hours prior to initiation of apheresis. (<a href="#S2.1">2.1</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:  If creatinine clearance is ≤ 50 mL/min, decrease dose by one-third to 0.16 mg/kg. (<a href="#S2.3">2.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Single-use vial containing 1.2 mL of a 20 mg/mL solution. (<a href="#S3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Mozobil. (<a href="#S4">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span> and Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span> have occurred. Monitor patients during and after completion of Mozobil administration. (<a href="#S5.1">5.1</a>)</li>
<li> Tumor Cell Mobilization in <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> Patients: Mozobil may mobilize leukemic cells and should not be used in <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> patients. (<a href="#S5.2">5.2</a>) </li>
<li> Hematologic Effects: Increased circulating leukocytes and decreased platelet counts have been observed.  Monitor blood cell counts and platelet counts during Mozobil use. (<a href="#S5.3">5.3</a>) </li>
<li> Potential for Tumor Cell Mobilization:  Tumor cells may be released from marrow during HSC mobilization with Mozobil and G-CSF.  Effect of reinfusion of tumor cells is unknown. (<a href="#S5.4">5.4</a>) </li>
<li> Potential for <span class="product-label-link" type="condition" conceptid="4120624" conceptname="Rupture of spleen">Splenic Rupture</span>: Evaluate patients who report left upper abdominal and/or scapular or <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">shoulder pain</span>. (<a href="#S5.5">5.5</a>) </li>
<li> Embryo-fetal Toxicity: May cause fetal harm.  Advise women not to become pregnant when taking Mozobil.  (<a href="#S5.6">5.6</a>,<a href="#S8.1"> 8.1</a>) </li>
</ul></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"> Most common adverse reactions (≥ 10%): <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. (<a href="#S6">6</a>)  </p>
<br><p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Genzyme Corporation at 1-877-4MOZOBIL or FDA at 1-800-FDA-1088 or </span></span><span class="Bold"><span class="Emphasis">www.fda.gov/medwatch</span></span> </p>
</div>
<div></div>
<div><div></div></div>
</div>
<div></div>
<div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dosage and Administration</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Concomitant Medications</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosing in Renal Impairment</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Tumor Cell Mobilization in <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> Patients</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Hematologic Effects</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Potential for Tumor Cell Mobilization</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Splenic Enlargement and Potential for Rupture</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Embryo-fetal Toxicity</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"> Mozobil<span class="Sup">®</span> (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (NHL) and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> (MM). </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dosage and Administration</h2>
<p class="First">Vials should be inspected visually for particulate matter and discoloration prior to administration and should not be used if there is particulate matter or if the solution is discolored.</p>
<p> Begin treatment with Mozobil after the patient has received G-CSF once daily for four days. <span class="Italics"><span class="Emphasis">[see</span></span><span class="Italics"><span class="Emphasis"><a href="#S2.2"> Dosage and Administration (2.2)</a></span></span><span class="Italics"><span class="Emphasis">] </span></span> Administer Mozobil approximately 11 hours prior to initiation of each apheresis for up to 4 consecutive days. </p>
<p style="border-left:1px solid;"><span class="XmChange">The recommended dose of Mozobil by subcutaneous injection is based on body weight:</span></p>
<ul class="Disc">
<li><p class="First" style="border-left:1px solid;"><span class="XmChange">20 mg fixed dose or 0.24 mg/kg of body weight for patients weighing ≤83 kg. <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span></span></p></li>
<li style="border-left:1px solid;"><span class="XmChange">0.24 mg/kg of body weight for patients weighing &gt;83 kg.</span></li>
</ul>
<p style="border-left:1px solid;"><span class="XmChange">Use the patient's actual body weight to calculate the volume of Mozobil to be administered. Each vial delivers 1.2 mL of 20 mg/mL solution, and the volume to be administered to patients should be calculated from the following equation:</span></p>
<p>    0.012 × patient's actual body weight (in kg) = volume to be administered (in mL)</p>
<p>In clinical studies, Mozobil dose has been calculated based on actual body weight in patients up to 175% of ideal body weight. Mozobil dose and treatment of patients weighing more than 175% of ideal body weight have not been investigated. </p>
<p> Based on increasing exposure with increasing body weight, the Mozobil dose should not exceed 40 mg/day. <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[see </span></span><a href="#S12.3">Clinical Pharmacology (12.3)</a></span></span><span class="Italics"><span class="Emphasis">]</span></span>  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Concomitant Medications</h2>
<p class="First"> Administer daily morning doses of G-CSF 10 micrograms/kg for 4 days prior to the first evening dose of Mozobil and on each day prior to apheresis. <span class="Italics"><span class="Emphasis">[see </span></span><span class="Italics"><span class="Emphasis"><a href="#S14"> Clinical Studies (14)</a></span></span><span class="Italics"><span class="Emphasis">]</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dosing in Renal Impairment</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"> In patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (estimated creatinine clearance (CL<span class="Sub">CR</span>) ≤ 50 mL/min), reduce the dose of Mozobil by one-third based on body weight category as shown in Table 1. If CL<span class="Sub">CR</span> is ≤ 50 mL/min the dose should not exceed 27 mg/day, as the mg/kg-based dosage results in increased plerixafor exposure with increasing body weight. <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[see </span></span><span class="Italics"><span class="Emphasis"><a href="#S12.3">                                          Clinical Pharmacology (12.3)</a></span></span></span></span><span class="Italics"><span class="Emphasis">]</span></span>  Similar systemic exposure is predicted if the dose is reduced by one-third in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared with subjects with normal renal function. <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[see </span></span><span class="Italics"><span class="Emphasis"><a href="#S12.3">                                          Clinical Pharmacology (12.3)</a></span></span></span></span><span class="Italics"><span class="Emphasis">]</span></span></span>  </p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Recommended Dosage of Mozobil in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></caption>
<colgroup>
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="33%">
</colgroup>
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center"><span class="XmChange">Estimated Creatinine Clearance<br>(mL/min)</span></th>
<th class="Rrule" align="center" colspan="2">Dose</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center"><span class="XmChange">Body Weight ≤ 83 kg</span></th>
<th class="Rrule" align="center">Body Weight &gt; 83 kg and &lt; 160 kg</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="XmChange">&gt; 50</span></td>
<td align="center">20 mg or 0.24 mg/kg once daily </td>
<td class="Lrule Rrule" align="center">0.24 mg/kg once daily (not to exceed 40 mg/day)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="center"><span class="XmChange">≤ 50</span></td>
<td align="center">13 mg or 0.16 mg/kg once daily </td>
<td class="Lrule Rrule" align="center">0.16 mg/kg once daily (not to exceed 27 mg/day)</td>
</tr>
</tbody>
</table>
<p> The following (Cockroft-Gault) formula may be used to estimate CL<span class="Sub">CR</span>:  </p>
<p>     Males:<br>    Creatinine clearance (mL/min) = <span class="Underline"><span class="Emphasis"><span class="Underline"><span class="Emphasis">weight (kg) × (140 – age in years)</span></span><br></span></span>                                                          72 × serum creatinine (mg/dL) </p>
<p>     Females:<br>    Creatinine clearance (mL/min) = 0.85 × value calculated for males </p>
<p>There is insufficient information to make dosage recommendations in patients on hemodialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Single-use vial containing 1.2 mL of a 20 mg/mL solution.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">							History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to Mozobil <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.  <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span> has occurred with use of Mozobil. 						</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> </h2>
<p class="First">									Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including anaphylactic-type reactions, some of which have been life-threatening with clinically significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> have occurred in patients receiving Mozobil <span class="Italics"> [see <a href="#S6.2"> Adverse Reactions (6.2)</a>]</span>. Observe patients for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> during and after Mozobil administration for at least 30 minutes and until clinically stable following completion of each administration. Only administer Mozobil when personnel and therapies are immediately available for the treatment of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>. 								</p>
<p>In clinical studies, mild or moderate <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> occurred within approximately 30 minutes after Mozobil administration in less than 1% of patients <span class="Italics"> [see<a href="#S6.1"> Adverse Reactions (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Tumor Cell Mobilization in <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemia</span> Patients</h2>
<p class="First">For the purpose of HSC mobilization, Mozobil may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. Therefore, Mozobil is not intended for HSC mobilization and harvest in patients with <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Hematologic Effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">Leukocytosis</span></span></p>
<p>Administration of Mozobil in conjunction with G-CSF increases circulating leukocytes as well as HSC populations. Monitor white blood cell counts during Mozobil use. <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3.2"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> has been observed in patients receiving Mozobil. Monitor platelet counts in all patients who receive Mozobil and then undergo apheresis. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Potential for Tumor Cell Mobilization</h2>
<p class="First">When Mozobil is used in combination with G-CSF for HSC mobilization‚ tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. The effect of potential reinfusion of tumor cells has not been well-studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Splenic Enlargement and Potential for Rupture</h2>
<p class="First">Higher absolute and relative spleen weights associated with extramedullary hematopoiesis were observed following prolonged (2 to 4 weeks) daily plerixafor SC administration in rats at doses approximately 4-fold higher than the recommended human dose based on body surface area. The effect of Mozobil on spleen size in patients was not specifically evaluated in clinical studies. Evaluate individuals receiving Mozobil in combination with G-CSF who report left <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span> and/or scapular or <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">shoulder pain</span> for splenic integrity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Embryo-fetal Toxicity</h2>
<p class="First">Mozobil may cause fetal harm when administered to a pregnant woman. Plerixafor is teratogenic in animals. There are no adequate and well-controlled studies in pregnant women using Mozobil. Advise women of childbearing potential to avoid becoming pregnant while receiving treatment with Mozobil<span class="Italics">. </span> If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. <span class="Italics"><span class="Emphasis">[see</span></span><span class="Italics"><span class="Emphasis"><a href="#S8.1"> Use In Specific Populations (8.1)</a></span></span><span class="Italics"><span class="Emphasis">]</span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling: </p>
<br><ul>
<li><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic shock</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li> Potential for tumor cell mobilization in <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> patients<span class="Italics"><span class="Emphasis"> [see <a href="#S5.2">Warnings and Precautions (5.2)</a>] </span></span>
</li>
<li> Increased circulating leukocytes and decreased platelet counts<span class="Italics"><span class="Emphasis"> [see <a href="#S5.3">Warnings and Precautions (5.3)</a>] </span></span>
</li>
<li>Potential for tumor cell mobilization <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li> Potential for splenic enlargement <span class="Italics"><span class="Emphasis"> [see <a href="#S5.5">Warnings and Precautions (5.5)</a>] </span></span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The most common adverse reactions (≥ 10%) reported in patients who received Mozobil in conjunction with G-CSF regardless of causality and more frequent with Mozobil than placebo during HSC mobilization and apheresis were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p> Safety data for Mozobil in combination with G-CSF were obtained from two randomized placebo-controlled studies (301 patients) and 10 uncontrolled studies (242 patients). Patients were primarily treated with Mozobil at daily doses of 0.24 mg/kg SC. Median exposure to Mozobil in these studies was 2 days (range 1 to 7 days).</p>
<p> In the two randomized studies in patients with NHL and MM, a total of 301 patients were treated in the Mozobil and G-CSF group and 292 patients were treated in the placebo and G-CSF group. Patients received daily morning doses of G-CSF 10 micrograms/kg for 4 days prior to the first dose of Mozobil 0.24 mg/kg SC or placebo and on each morning prior to apheresis. The adverse reactions that occurred in ≥ 5% of the patients who received Mozobil regardless of causality and were more frequent with Mozobil than placebo during HSC mobilization and apheresis are shown in Table 2.  </p>
<br><a name="table2"></a><table width="90%">
<caption><span>Table 2: Adverse Reactions in ≥ 5% of Non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Lymphoma</span> and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> Patients Receiving Mozobil® and More Frequent than Placebo During HSC Mobilization and Apheresis</span></caption>
<colgroup>
<col align="left" valign="top" width="28%">
<col align="left" valign="top" width="12%">
<col align="left" valign="top" width="12%">
<col align="left" valign="top" width="12%">
<col align="left" valign="top" width="12%">
<col align="left" valign="top" width="12%">
<col align="left" valign="top" width="12%">
</colgroup>
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="3"></th>
<th class="Rrule" align="center" colspan="6"> Percent of Patients (%)</th>
</tr>
<tr class="Botrule">
<th class="Lrule Rrule" align="center" colspan="3">  Mozobil® and G-CSF<br>(n = 301) </th>
<th class="Rrule" align="center" colspan="3"> Placebo and G-CSF<br>(n = 292) </th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center">All Grades<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>   </th>
<th class="Rrule" align="center">Grade 3</th>
<th class="Rrule" align="center">Grade 4</th>
<th class="Rrule" align="center">All Grades </th>
<th class="Rrule" align="center">Grade 3</th>
<th class="Rrule" align="center">Grade 4</th>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Grades based on criteria from the World Health Organization (WHO)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span></span></td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center"> 37</td>
<td class="Rrule" align="center">&lt; 1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">17</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Vomiting    </td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">&lt; 1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Emphasis">General disorders and administration site conditions </span></span></td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Injection site reactions        </td>
<td class="Rrule" align="center">34</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">10</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Fatigue </td>
<td class="Rrule" align="center">27</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">25</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Emphasis">Musculoskeletal and connective tissue disorders     </span></span></td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    Arthralgia </td>
<td class="Rrule" align="center">13</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></span></td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">22</td>
<td class="Rrule" align="center">&lt; 1</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">21</td>
<td class="Rrule" align="center">1</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">    <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center">11</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">6</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold"><span class="Emphasis">Psychiatric disorders</span></span></td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
<td class="Rrule" align="center"> </td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">   <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Rrule" align="center">7</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p>In the randomized studies, 34% of patients with NHL or MM had mild to moderate <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> at the site of subcutaneous administration of Mozobil. These included <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, irritation, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Mild to moderate <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> were observed in less than 1% of patients within approximately 30 min after Mozobil administration, including one or more of the following: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (n = 2), <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">periorbital swelling</span> (n = 2), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (n = 1) or <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> (n = 1). Symptoms generally responded to treatments (e.g., antihistamines, corticosteroids, hydration or supplemental oxygen) or resolved spontaneously. </p>
<p> <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">Vasovagal reactions</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and/or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> can occur following subcutaneous injections.<span class="Italics"><span class="Emphasis"> </span></span>In Mozobil oncology and healthy volunteer clinical studies, less than 1% of subjects experienced <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">vasovagal reactions</span> following subcutaneous administration of Mozobil doses ≤ 0.24 mg/kg. The majority of these events occurred within 1 hour of Mozobil administration. Because of the potential for these reactions, appropriate precautions should be taken. </p>
<p> Other adverse reactions in the randomized studies that occurred in &lt; 5% of patients but were reported as related to Mozobil during HSC mobilization and apheresis included <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4009388" conceptname="Perioral numbness">hypoesthesia oral</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, and <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span>.</p>
<p>Hyperleukocytosis: In clinical trials, white blood cell counts of 100,000/mcL or greater were observed, on the day prior to or any day of apheresis, in 7% of patients receiving Mozobil and in 1% of patients receiving placebo. No complications or clinical symptoms of <span class="product-label-link" type="condition" conceptid="4147999" conceptname="Leukostasis">leukostasis</span> were observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Post-marketing Experience</h2>
<p class="First">In addition to adverse reactions reported from clinical trials, the following adverse reactions have been reported from post-marketing experience with Mozobil. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: </span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span></p>
<p><span class="Italics">Psychiatric disorders</span>: <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span> and <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"> Based on <span class="Italics"><span class="Emphasis">in vitro</span></span> data, plerixafor is not a substrate, inhibitor or inducer of human cytochrome P450 isozymes. Plerixafor is not likely to be implicated in <span class="Italics"><span class="Emphasis">in vivo</span></span> drug-drug interactions involving cytochrome P450s. At concentrations similar to what are seen clinically, plerixafor did not act as a substrate or inhibitor of P-glycoprotein in an <span class="Italics"><span class="Emphasis">in vitro</span></span> study. <span class="Italics"><span class="Emphasis"> [see <a href="#S12.3">Clinical Pharmacology (12.3)</a>] </span></span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Pregnancy Category D</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Risk Summary</span></p>
<p>Mozobil may cause fetal harm when administered to a pregnant woman. Plerixafor is teratogenic in animals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Animal Data</span></p>
<p>Plerixafor administered to pregnant rats induced embryo-fetal toxicities including <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>, increased resorptions and post-implantation loss, decreased fetal weights, <span class="product-label-link" type="condition" conceptid="434143" conceptname="Anophthalmos">anophthalmia</span>, shortened digits, cardiac interventricular septal defect, ringed aorta, globular heart, <span class="product-label-link" type="condition" conceptid="4043738" conceptname="Hydrocephalus">hydrocephaly</span>, dilatation of olfactory ventricles, and retarded skeletal development. Embryo-fetal toxicities occurred mainly at a dose of 90 mg/m<span class="Sup">2</span>                           (approximately 10 times the recommended human dose of 0.24 mg/kg when compared on a mg/m<span class="Sup">2</span> basis or 10 times the AUC in subjects with normal renal function who received a single dose of 0.24 mg/kg).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether plerixafor is excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants from Mozobil, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of Mozobil in pediatric patients have not been established in controlled clinical studies. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total number of subjects in controlled clinical studies of Mozobil, 24% were 65 and over, while 0.8% were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p> Since plerixafor is mainly excreted by the kidney, no dose modifications are necessary in elderly individuals with normal renal function.  In general, care should be taken in dose selection for elderly patients due to the greater frequency of decreased renal function with advanced age.  Dosage adjustment in elderly patients with CL<span class="Sub">CR</span>                           ≤ 50 mL/min is recommended. <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[see </span></span><a href="#S2.3">Dosage and Administration (2.3)</a><span class="Italics"><span class="Emphasis"> and </span></span><a href="#S12.3">Clinical Pharmacology (12.3)</a><span class="Italics"><span class="Emphasis">]</span></span></span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First"> In patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> ≤ 50 mL/min), reduce the dose of Mozobil by one-third to 0.16 mg/kg. <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[see </span></span><a href="#S2.3">Dosage and Administration (2.3)</a><span class="Italics"><span class="Emphasis"> and </span></span><a href="#S12.3">Clinical Pharmacology (12.3)</a><span class="Italics"><span class="Emphasis">]</span></span></span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Based on limited data at doses above the recommended dose of 0.24 mg/kg SC, the frequency of <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>, <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">vasovagal reactions</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and/or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> may be higher.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Mozobil (plerixafor injection) is a sterile, preservative-free, clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, isotonic solution for subcutaneous injection. Each mL of the sterile solution contains 20 mg of plerixafor.  Each single-use vial is filled to deliver 1.2 mL of the sterile solution that contains 24 mg of plerixafor and 5.9 mg of sodium chloride in Water for Injection adjusted to a pH of 6.0 to 7.5 with hydrochloric acid and with sodium hydroxide, if required.  </p>
<p> Plerixafor is a hematopoietic stem cell mobilizer with a chemical name l, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane.  It has the molecular formula C<span class="Sub">28</span>H<span class="Sub">54</span>N<span class="Sub">8.  </span>The molecular weight of plerixafor is 502.79 g/mol. The structural formula is provided in <a href="#figure1">Figure 1</a>. </p>
<p><a name="figure1"></a><span class="Bold"><span class="Emphasis">Figure 1: Structural Formula </span></span></p>
<div class="Figure"><img alt="Figure 1: Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ed08d2b-5051-46b2-aa37-1d6275bf9003&amp;name=mozobil-01.jpg"></div>
<p>Plerixafor is a white to off-white crystalline solid.  It is hygroscopic. Plerixafor has a typical melting point of 131.5 °C. The partition coefficient of plerixafor between 1-octanol and pH 7 aqueous buffer is &lt; 0.1.</p>
<br>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"> Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1α (SDF-1α).  SDF-1α and CXCR4 are recognized to play a role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the marrow matrix, either directly via SDF-1α or through the induction of other <span class="product-label-link" type="condition" conceptid="4175338" conceptname="Adhesion">adhesion</span> molecules. Treatment with plerixafor resulted in <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span> and elevations in circulating hematopoietic progenitor cells in mice, dogs and humans.  CD34+ cells mobilized by plerixafor were capable of engraftment with long-term repopulating capacity up to one year in canine transplantation models.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"> Data on the fold increase in peripheral blood CD34+ cell count (cells/mcL) by apheresis day were evaluated in two placebo-controlled clinical studies in patients with NHL and MM (Study 1 and Study 2, respectively). The fold increase in CD34+ cell count (cells/mcL) over the 24-hour period starting from the day prior to the first apheresis and ending the next morning just before the first apheresis is summarized in Table 3.  During this 24-hour period, a single dose of Mozobil or placebo was administered 10 to 11 hours prior to apheresis. </p>
<a name="table3"></a><table width="70%">
<caption><span>Table 3: Fold Increase in Peripheral Blood CD34+ Cell Count Following Pretreatment with G-CSF and Administration of Plerixafor</span></caption>
<colgroup>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="25%">
</colgroup>
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center" rowspan="2" valign="middle"> Study </th>
<th class="Rrule" align="center" colspan="2">Mozobil® and G-CSF</th>
<th class="Rrule" align="center" colspan="2">Placebo and G-CSF</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center"> Median</th>
<th class="Rrule" align="center"> Mean (SD)</th>
<th class="Rrule" align="center">  Median  </th>
<th class="Rrule" align="center"> Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"> Study 1</td>
<td class="Rrule" align="center"> 5.0</td>
<td class="Rrule" align="center"> 6.1 (5.4)</td>
<td class="Rrule" align="center"> 1.4</td>
<td class="Rrule" align="center"> 1.9 (1.5)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"> Study 2</td>
<td class="Rrule" align="center"> 4.8</td>
<td class="Rrule" align="center"> 6.4 (6.8)</td>
<td class="Rrule" align="center"> 1.7</td>
<td class="Rrule" align="center"> 2.4 (7.3)</td>
</tr>
</tbody>
</table>
<p>In pharmacodynamic studies of Mozobil in healthy volunteers, peak mobilization of CD34+ cells was observed between 6 and 9 hours after administration. In pharmacodynamic studies of Mozobil in conjunction with G-CSF in healthy volunteers, a sustained elevation in the peripheral blood CD34+ count was observed from 4 to 18 hours after plerixafor administration with a peak CD34+ count between 10 and 14 hours.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">QT/QTc Prolongation</span></p>
<p>There is no indication of a QT/QTc prolonging effect of Mozobil in single doses up to 0.40 mg/kg. In a randomized, double-blind, crossover study, 48 healthy subjects were administered a single subcutaneous dose of plerixafor (0.24 mg/kg and 0.40 mg/kg) and placebo. Peak concentrations for 0.40 mg/kg Mozobil were approximately 1.8-fold higher than the peak concentrations following the 0.24 mg/kg single subcutaneous dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The single-dose pharmacokinetics of plerixafor 0.24 mg/kg were evaluated in patients with NHL and MM following pre-treatment with G-CSF (10 micrograms/kg once daily for 4 consecutive days).  Plerixafor exhibits linear kinetics between the 0.04 mg/kg to 0.24 mg/kg dose range.  The pharmacokinetics of plerixafor were similar across clinical studies in healthy subjects who received plerixafor alone and NHL and MM patients who received plerixafor in combination with G-CSF.</p>
<p> A population pharmacokinetic analysis incorporated plerixafor data from 63 subjects (NHL patients, MM patients, subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, and healthy subjects) who received a single SC dose (0.04 mg/kg to 0.24 mg/kg) of plerixafor.  A two-compartment disposition model with first order absorption and elimination was found to adequately describe the plerixafor concentration-time profile. Significant relationships between clearance and creatinine clearance (CL<span class="Sub">CR</span>), as well as between central volume of distribution and body weight were observed.  The distribution half-life (t<span class="Sub">1/2α</span>) was estimated to be 0.3 hours and the terminal population half-life (t<span class="Sub">1/2β</span>) was 5.3 hours in patients with normal renal function. </p>
<p> The population pharmacokinetic analysis showed that the mg/kg-based dosage results in an increased plerixafor exposure (AUC<span class="Sub">0–24h</span>) with increasing body weight.  In order to compare the pharmacokinetics and pharmacodynamics of plerixafor following 0.24 mg/kg-based and fixed (20 mg) doses, a follow-up trial was conducted in patients with NHL (N=61) who were treated with 0.24 mg/kg or 20 mg of plerixafor. The trial was conducted in patients weighing 70 kg or less. The fixed 20 mg dose showed 1.43-fold higher exposure (AUC<span class="Sub">0–10h</span>) than the 0.24 mg/kg dose (Table 4).  The fixed 20 mg dose also showed numerically higher response rate (5.2% [60.0% vs 54.8%] based on the local lab data and 11.7% [63.3% vs 51.6%] based on the central lab data) in attaining the target of ≥ 5 × 10<span class="Sup">6</span> CD34+ cells/kg than the mg/kg-based dose.  However, the median time to reach ≥ 5 × 10<span class="Sup">6</span> CD34+ cells/kg was 3 days for both treatment groups, and the safety profile between the groups was similar. Based on these results, further analysis was conducted by FDA reviewers and a body weight of 83 kg was selected as an appropriate cut-off point to transition patients from fixed to weight based dosing.   </p>
<table width="60%">
<caption><span>Table 4. Systemic Exposure (AUC<span class="Sub">0–10h</span>) comparisons of fixed and weight based regimens</span></caption>
<col align="center" valign="middle" width="50%">
<col align="center" valign="middle" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Regimen</th>
<th class="Rrule" align="center">Geometric Mean AUC</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Fixed 20 mg (n=30)</td>
<td class="Rrule" align="center">3991.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">0.24 mg/kg (n=31)</td>
<td class="Rrule" align="center">2792.7</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">Ratio (90% CI)</td>
<td class="Rrule" align="center">1.43 (1.32,1.54)</td>
</tr>
</tbody>
</table>
<p>There is limited experience with the 0.24 mg/kg dose of plerixafor in patients weighing above 160 kg.  Therefore the dose should not exceed that of a 160 kg patient (i.e., 40 mg/day if CL<span class="Sub">CR</span> is &gt; 50 mL/min and 27 mg/day if CL<span class="Sub">CR</span> is ≤ 50 mL/min).  <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[see </span></span><a href="#S2.1">Dosage and Administration (2.1</a><span class="Italics"><span class="Emphasis">, </span></span><a href="#S2.3">2.3)</a><span class="Italics"><span class="Emphasis">]</span></span></span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold Italics">Absorption</span></p>
<p>Peak plasma concentrations occurred at approximately 30 – 60 minutes after a SC dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold Italics">Distribution</span></p>
<p>Plerixafor is bound to human plasma proteins up to 58%. The apparent volume of distribution of plerixafor in humans is 0.3 L/kg demonstrating that plerixafor is largely confined to, but not limited to, the extravascular fluid space.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold Italics">Metabolism</span></p>
<p>The metabolism of plerixafor was evaluated with <span class="Italics"><span class="Emphasis">in vitro</span></span> assays.  Plerixafor is not metabolized as shown in assays using human liver microsomes or human primary hepatocytes and does not exhibit inhibitory activity <span class="Italics"><span class="Emphasis">in vitro</span></span> towards the major drug metabolizing cytochrome P450 enzymes (1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4/5). In<span class="Italics"><span class="Emphasis"> in vitro</span></span> studies with human hepatocytes, plerixafor does not induce CYP1A2, CYP2B6, or CYP3A4 enzymes. These findings suggest that plerixafor has a low potential for involvement in cytochrome P450-dependent drug-drug interactions. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold Italics">Elimination</span></p>
<p>The major route of elimination of plerixafor is urinary. Following a 0.24 mg/kg dose in healthy volunteers with normal renal function, approximately 70% of the dose was excreted in the urine as the parent drug during the first 24 hours following administration. In studies with healthy subjects and patients, the terminal half-life in plasma ranges between 3 and 5 hours. At concentrations similar to what are seen clinically, plerixafor did not act as a substrate or inhibitor of P-glycoprotein in an <span class="Italics"><span class="Emphasis">in vitro</span></span> study with MDCKII and MDCKII-MDR1 cell models. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>Following a single 0.24 mg/kg SC dose, plerixafor clearance was reduced in subjects with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and was positively correlated with CL<span class="Sub">CR</span>.  The mean AUC<span class="Sub">0–24h</span> of plerixafor in subjects with mild (CL<span class="Sub">CR</span> 51–80 mL/min), moderate (CL<span class="Sub">CR</span> 31–50 mL/min), and severe (CL<span class="Sub">CR</span>                           &lt; 31 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was 7%, 32%, and 39% higher than healthy subjects with normal renal function, respectively.  <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> had no effect on C<span class="Sub">max</span>. A population pharmacokinetic analysis indicated an increased exposure (AUC<span class="Sub">0–24h</span>)<span class="Sub"> </span>in patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared to patients with CL<span class="Sub">CR</span> &gt; 50 mL/min. These results support a dose reduction of one-third in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">CR</span> ≤ 50 mL/min) in order to match the exposure in patients with normal renal function. The population pharmacokinetic analysis showed that the mg/kg-based dosage results in an increased plerixafor exposure (AUC<span class="Sub">0–24h</span>) with increasing body weight; therefore if CL<span class="Sub">CR</span> is ≤ 50 mL/min the dose should not exceed 27 mg/day.  <span class="Italics">[see <a href="#S2.3">Dosage and Administration (2.3)</a>]</span></p>
<p>Since plerixafor is primarily eliminated by the kidneys, coadministration of plerixafor with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of plerixafor or the coadministered drug.  The effects of coadministration of plerixafor with other drugs that are renally eliminated or are known to affect renal function have not been evaluated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold Italics">Race</span></p>
<p>Clinical data show similar plerixafor pharmacokinetics for Caucasians and African-Americans, and the effect of other racial/ethnic groups has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Bold Italics">Gender</span></p>
<p>Clinical data show no effect of gender on plerixafor pharmacokinetics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Bold Italics">Age</span></p>
<p>Clinical data show no effect of age on plerixafor pharmacokinetics</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies with plerixafor have not been conducted.</p>
<p> Plerixafor was not genotoxic in an <span class="Italics"><span class="Emphasis">in vitro</span></span> bacterial mutation assay (Ames test in <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span></span>), an <span class="Italics"><span class="Emphasis">in vitro</span></span> chromosomal aberration test using V79 Chinese hamster cells, or an <span class="Italics"><span class="Emphasis">in vivo</span></span> bone marrow micronucleus test in rats after subcutaneous doses up to 25 mg/kg (150 mg/m<span class="Sup">2</span>). </p>
<p>The effect of plerixafor on human fertility is unknown.  The effect of plerixafor on male or female fertility was not studied in designated reproductive toxicology studies.  The staging of spermatogenesis measured in a 28-day repeated dose toxicity study in rats revealed no abnormalities considered to be related to plerixafor.  No histopathological evidence of toxicity to male or female reproductive organs was observed in 28-day repeated dose toxicity studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy and safety of Mozobil in conjunction with G-CSF in non-Hodgkin's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (NHL) and <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span> (MM) were evaluated in two placebo-controlled studies (Studies 1 and 2).  Patients were randomized to receive either Mozobil 0.24 mg/kg or placebo on each evening prior to apheresis. Patients received daily morning doses of G-CSF 10 micrograms/kg for 4 days prior to the first dose of Mozobil or placebo and on each morning prior to apheresis. Two hundred and ninety-eight (298) NHL patients were included in the primary efficacy analyses for Study 1. The mean age was 55 years (range 29–75) and 58 years (range 22–75) in the Mozobil and placebo groups, respectively, and 93% of subjects were Caucasian. In study 2, 302 patients with MM were included in the primary efficacy analyses. The mean age (58years) and age range (28–75) were similar in the Mozobil and placebo groups, and 81% of subjects were Caucasian.</p>
<p> In Study 1, 59% of NHL patients who were mobilized with Mozobil and G-CSF collected ≥ 5 × 10<span class="Sup">6</span> CD34+ cells/kg from the peripheral blood in four or fewer apheresis sessions, compared with 20% of patients who were mobilized with placebo and G-CSF (p &lt; 0.001). Other CD34+ cell mobilization outcomes showed similar findings (Table 5).  </p>
<br><a name="table5"></a><table width="75%">
<caption><span>Table 5: Study 1 Efficacy Results - CD34+ Cell Mobilization in NHL Patients</span></caption>
<colgroup>
<col align="left" valign="top" width="49%">
<col align="left" valign="top" width="17%">
<col align="left" valign="top" width="17%">
<col align="left" valign="top" width="17%">
</colgroup>
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Efficacy Endpoint</th>
<th class="Rrule" align="center" valign="middle">Mozobil® and G-CSF<br>(n = 150) </th>
<th class="Rrule" align="center" valign="middle">Placebo and G-CSF<br>(n = 148) </th>
<th class="Rrule" align="center" valign="middle">p-value<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>  </th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>p-value calculated using Pearson's Chi-Squared test</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"> Patients achieving ≥ 5 × 10<span class="Sup">6</span> cells/kg in ≤ 4 apheresis days </td>
<td class="Rrule" align="center">89 (59%)</td>
<td class="Rrule" align="center">29 (20%)</td>
<td class="Rrule" align="center">&lt; 0.001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"> Patients achieving ≥ 2 × 10<span class="Sup">6</span> cells/kg in ≤ 4 apheresis days </td>
<td class="Rrule" align="center">130 (87%)</td>
<td class="Rrule" align="center">70 (47%)</td>
<td class="Rrule" align="center">&lt; 0.001</td>
</tr>
</tbody>
</table>
<p> The median number of days to reach ≥ 5 × 10<span class="Sup">6</span> CD34+ cells/kg was 3 days for the Mozobil group and not evaluable for the placebo group. Table 6 presents the proportion of patients who achieved ≥ 5 × 10<span class="Sup">6</span> CD34+ cells/kg by apheresis day. </p>
<br><a name="table6"></a><table width="75%">
<caption><span> Table 6: Study 1 Efficacy Results – Proportion of Patients Who Achieved ≥ 5 × 10<span class="Sup">6</span> CD34+ cells/kg by Apheresis Day in NHL Patients </span></caption>
<colgroup>
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="40%">
<col align="left" valign="top" width="40%">
</colgroup>
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Days</th>
<th class="Rrule" align="center" valign="middle">Proportion<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a> in Mozobil® and G-CSF<br>(n=147<a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>)</th>
<th class="Rrule" align="center" valign="middle">Proportion<a href="#footnote-3" class="Sup">*</a> in Placebo and G-CSF<br>(n=142<a href="#footnote-4" class="Sup">†</a>) </th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Percents determined by Kaplan Meier method</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>n includes all patients who received at least one day of apheresis </dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"><span class="Bold">1</span></td>
<td class="Rrule" align="center">27.9%</td>
<td class="Rrule" align="center">4.2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">2</span></td>
<td class="Rrule" align="center">49.1%</td>
<td class="Rrule" align="center">14.2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"><span class="Bold">3</span></td>
<td class="Rrule" align="center">57.7%</td>
<td class="Rrule" align="center">21.6%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"><span class="Bold">4</span></td>
<td class="Rrule" align="center">65.6%</td>
<td class="Rrule" align="center">24.2%</td>
</tr>
</tbody>
</table>
<p> In Study 2, 72% of MM patients who were mobilized with Mozobil and G-CSF collected ≥ 6 × 10<span class="Sup">6</span> CD34+ cells/kg from the peripheral blood in two or fewer apheresis sessions, compared with 34% of patients who were mobilized with placebo and G-CSF (p &lt; 0.001). Other CD34+ cell mobilization outcomes showed similar findings (Table 7).  </p>
<a name="table7"></a><table width="75%">
<caption><span>Table 7: Study 2 Efficacy Results – CD34+ Cell Mobilization in <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple Myeloma</span> Patients</span></caption>
<colgroup>
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="17%">
<col align="left" valign="top" width="17%">
<col align="center" valign="top" width="16%">
</colgroup>
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle"> Efficacy Endpoint   </th>
<th class="Rrule" align="center" valign="middle">  Mozobil® and G-CSF<br>(n = 148) </th>
<th class="Rrule" align="center" valign="middle"> Placebo and G-CSF<br>(n = 154) </th>
<th class="Rrule" align="center" valign="middle">  p-value<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> </th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>p-value calculated using Pearson's Chi-Squared test</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"> Patients achieving ≥ 6 × 10<span class="Sup">6</span> cells/kg in ≤ 2 apheresis days </td>
<td class="Rrule" align="center"> 106 (72%)</td>
<td class="Rrule" align="center"> 53 (34%)</td>
<td class="Rrule" align="center"> &lt; 0.001</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"> Patients achieving ≥ 6 × 10<span class="Sup">6</span> cells/kg in ≤ 4 apheresis days   </td>
<td class="Rrule" align="center">112 (76%)</td>
<td class="Rrule" align="center">79 (51%)</td>
<td class="Rrule" align="center"> &lt; 0.001</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"> Patients achieving ≥ 2 × 10<span class="Sup">6</span> cells/kg in ≤ 4 apheresis days    </td>
<td class="Rrule" align="center">141 (95%)</td>
<td class="Rrule" align="center"> 136 (88%)</td>
<td class="Rrule" align="center"> 0.028</td>
</tr>
</tbody>
</table>
<p> The median number of days to reach ≥ 6 × 10<span class="Sup">6</span> CD34+ cells/kg was 1 day for the Mozobil group and 4 days for the placebo group. Table 8 presents the proportion of patients who achieved ≥ 6 × 10<span class="Sup">6</span> CD34+ cells/kg by apheresis day. </p>
<a name="table8"></a><table width="75%">
<caption><span> Table 8: Study 2 – Proportion of Patients Who Achieved ≥ 6 × 10<span class="Sup">6</span> CD34+ cells/kg by Apheresis Day in MM Patients </span></caption>
<colgroup>
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="40%">
<col align="center" valign="top" width="40%">
</colgroup>
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">Days </th>
<th class="Rrule" align="center" valign="middle">Proportion<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a> in Mozobil® and G-CSF<br>(n=144<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>)  </th>
<th class="Rrule" align="center" valign="middle">Proportion<a href="#footnote-6" class="Sup">*</a> in Placebo and G-CSF<br>(n=150<a href="#footnote-7" class="Sup">†</a>)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Percents determined by Kaplan Meier method</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>n includes all patients who received at least one day of apheresis</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center"> <span class="Bold">1</span>
</td>
<td class="Rrule" align="center"> 54.2%</td>
<td class="Rrule" align="center"> 17.3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"> <span class="Bold">2</span>
</td>
<td class="Rrule" align="center"> 77.9%</td>
<td class="Rrule" align="center"> 35.3%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center"> <span class="Bold">3</span>
</td>
<td class="Rrule" align="center"> 86.8%</td>
<td class="Rrule" align="center"> 48.9%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center"> <span class="Bold">4</span>
</td>
<td class="Rrule" align="center"> 86.8%</td>
<td class="Rrule" align="center"> 55.9%</td>
</tr>
</tbody>
</table>
<p>Multiple factors can influence time to engraftment and graft durability following stem cell transplantation. For transplanted patients in the Phase 3 studies, time to neutrophil and platelet engraftment and graft durability were similar across the treatment groups. </p>
<br>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Each single-use vial is filled to deliver 1.2 mL of 20 mg/mL solution containing 24 mg of plerixafor.</p>
<p>NDC Number: 0024-5862-01</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<ul>
<li> Store at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); excursions permitted to 15<span class="Sup">o</span>–30<span class="Sup">o</span>C (59<span class="Sup">o</span>–86<span class="Sup">o</span>F). [see USP Controlled Room temperature] </li>
<li>Each vial of Mozobil is intended for single use only. Any unused drug remaining after injection must be discarded.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients of the potential for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, including signs and symptoms such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">periorbital swelling</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, or <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> during and following Mozobil injection and to report these symptoms immediately to a health care professional <span class="Italics">[see <a href="#S6.1">Adverse Reactions (6.1)</a>, <a href="#S6.2">(6.2)</a>]</span>. </p>
<p> Advise patients to inform a health care professional immediately if symptoms of <span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">vasovagal reactions</span> such as <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occur during or shortly after their Mozobil injection. <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[see </span></span><span class="Italics"><span class="Emphasis"><a href="#S6.1">Adverse Reactions (6.1)</a></span></span><span class="Italics"><span class="Emphasis">]</span></span></span></span></p>
<p> Advise patients who experience <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, or reaction at the site of injection to notify a health care professional, as these symptoms have been treated with over-the-counter medications during clinical trials. <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[see </span></span><span class="Italics"><span class="Emphasis"><a href="#S6.1">Adverse Reactions (6.1)</a></span></span><span class="Italics"><span class="Emphasis">]</span></span></span></span></p>
<p> Advise patients that Mozobil may cause <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span>, including <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. Patients should be told how to manage specific <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disorders</span> and to inform their health care professional if severe events occur following Mozobil injection. <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[see </span></span><span class="Italics"><span class="Emphasis"><a href="#S6.1">Adverse Reactions (6.1)</a></span></span><span class="Italics"><span class="Emphasis">]</span></span></span></span></p>
<p> Advise female patients with reproductive potential to use effective contraceptive methods during Mozobil use. <span class="Italics"><span class="Emphasis">[see </span></span><span class="Italics"><span class="Emphasis"><a href="#S5.6">Warnings and Precautions (5. 6)</a></span></span><span class="Italics"><span class="Emphasis"> and </span></span><span class="Italics"><span class="Emphasis"><a href="#S8.1">Use In Specific Populations (8.1)</a></span></span><span class="Italics"><span class="Emphasis">]</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured by: Patheon UK Ltd., Swindon, UK</p>
<p>Manufactured for: Genzyme Corporation, 500 Kendall Street, Cambridge, MA 02142 USA</p>
<br><p>©2015 Genzyme Corporation. All rights reserved. <br> Mozobil is a registered trademark of Genzyme Corporation.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d0d2e68e-73cc-483d-92b6-9994162d4b37"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1.2 mL Vial Carton</span></p>
<p><span class="Bold">Mozobil<span class="Sup">®</span><br>(plerixafor injection)</span></p>
<p><span class="Bold">24 mg/1.2 mL</span><br>(20 mg/mL)</p>
<p>For single use only</p>
<p><span class="Bold">For subcutaneous <br> injection only</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">genzyme</span></p>
<br><p><img alt="Principal Display Panel - 1.2 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0ed08d2b-5051-46b2-aa37-1d6275bf9003&amp;name=mozobil-02.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOZOBIL 		
					</strong><br><span class="contentTableReg">plerixafor solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0024-5862</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PLERIXAFOR</strong> (PLERIXAFOR) </td>
<td class="formItem">PLERIXAFOR</td>
<td class="formItem">24 mg  in 1.2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">5.9 mg  in 1.2 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0024-5862-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.2 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022311</td>
<td class="formItem">09/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genzyme Limited</td>
<td class="formItem"></td>
<td class="formItem">229522842</td>
<td class="formItem">MANUFACTURE(0024-5862), ANALYSIS(0024-5862), LABEL(0024-5862), PACK(0024-5862)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon UK Limited</td>
<td class="formItem"></td>
<td class="formItem">237710418</td>
<td class="formItem">MANUFACTURE(0024-5862), ANALYSIS(0024-5862)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>5db76e80-fb23-492a-88bc-68e8fc1293b3</div>
<div>Set id: 0ed08d2b-5051-46b2-aa37-1d6275bf9003</div>
<div>Version: 6</div>
<div>Effective Time: 20150806</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
